Browse this week's featured selection of scientific publications
A new selection of scientific publications relating to the latest developments in immunotherapy are added to our website weekly.
Here are are a few highlights from this week:
- Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial (Blood) - MCL remains an incurable disease and innovative approaches are needed: A non-chemotherapeutic triplet of ibrutinib, obinutuzumab, and venetoclax showed to be well tolerated and highly active in this phase 1/2 trial.
- Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer (Nat Rev Clin Oncol) - In this Consensus Statement, members of several international societies collaborated to provide updated comprehensive recommendations for the care of children, adolescents and young adults receiving cancer immunotherapies.
- CRS-related coagulopathy in BCMA targeted CAR-T therapy: a retrospective analysis in a phase I/II clinical trial (Bone Marrow Transplant) - Results from a phase 1/2 study uncover a relationship between coagulation disorder and CRS and suggest how coagulation dysfunction can be managed with daily monitoring and early intervention.
- Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy and Safety by Baseline CD22 (Clin Cancer Res) - ALL patients with high CD22 expression and normal cytogenetics benefits the most from inotuzumab therapy, according to this analysis of the INO-VATE trial.
You can access our complete resource library of scientific publications here.
Last Updated on Wednesday 03 March 2021.